Chronic obstructive pulmonary disease

Clinical Study for COPD Patients Opens to Oklahoma County and Pottawatomie County Residents

Retrieved on: 
Monday, January 29, 2024
Men, Research, Other Health, Pharmaceutical, Consumer, Clinical Trials, Science, Biotechnology, Women, Seniors, FDA, Health, Other Science, Risk, Mortality, Quality of life, Chronic obstructive pulmonary disease, AstraZeneca, Patient, Medicine, Smoking, COPD, Nursing

Despite available treatments like inhalers, many COPD patients still struggle to manage their symptoms effectively.

Key Points: 
  • Despite available treatments like inhalers, many COPD patients still struggle to manage their symptoms effectively.
  • "Our community now has the opportunity to contribute to this crucial research effort, potentially changing the way we approach COPD care."
  • The research study is enrolling for COPD patients 40 to 80 years of age, who have a history of smoking and are at high risk of exacerbations.
  • The local setting provides residents of Choctaw and surrounding communities the option to participate in clinical studies close to home.

AllerVie Health Expands Technology Infrastructure to Prioritize Innovation and Patient Experience

Retrieved on: 
Tuesday, January 23, 2024
Software, Practice Management, General Health, Health, Medical Devices, Health Technology, Technology, Apps, Applications, Cystic fibrosis, Patient, Chronic obstructive pulmonary disease, EMR, Asthma, Allergy, Communication, COPD, DLCO, Spirometry, Growth

"We are excited about our technology transformations this year and how they are enabling us to advance patient care and outcomes," said Chris Roussos, CEO of AllerVie Health.

Key Points: 
  • "We are excited about our technology transformations this year and how they are enabling us to advance patient care and outcomes," said Chris Roussos, CEO of AllerVie Health.
  • Key highlights of digital advancements include:
    In 2023, AllerVie Health expanded its deployment of a state-of-the-art pulmonary function testing solution to 30 clinics nationwide.
  • AllerVie Health implemented a new electronic medical record (EMR) system in 14 clinics across Florida and Georgia during 2023.
  • AllerVie Health's collaboration with a prominent digital health company specializing in respiratory health management broadens the utilization of a portable digital respiratory health tool and app across a more extensive range of clinics within the AllerVie Health network.

Global Ultrasonic Nebulizer Market to Reach US$ 325.6 Million by 2030, Rising at a CAGR of 5.9% | Report by CoherentMI

Retrieved on: 
Tuesday, January 16, 2024
Cystic fibrosis, World Health Organization, Patient, Chronic obstructive pulmonary disease, Research, Incidence, Hospital, Inhalation, Agilent Technologies, U22, Ultrasound, Asthma, Administration, Growth, Quality of life, Respiratory system, WHO, Health, Omron, Particle size, Prevalence, Pharmaceutical industry

Among the end users, hospitals and clinics are expected to dominate the global ultrasonic nebulizer market.

Key Points: 
  • Among the end users, hospitals and clinics are expected to dominate the global ultrasonic nebulizer market.
  • Key players operating in the global ultrasonic nebulizer market include Philips Healthcare, Omron, PARI Medical, BD, and Agilent Technologies, among others.
  • Large-volume ultrasonic nebulizers are expected to dominate the global ultrasonic nebulizer market in terms of product type.
  • Overall, the global ultrasonic nebulizer market offers lucrative opportunities in large-volume nebulizers for COPD treatment and the growing demand for home healthcare solutions.

Global Ultrasonic Nebulizer Market to Reach US$ 325.6 Million by 2030, Rising at a CAGR of 5.9% | Report by CoherentMI

Retrieved on: 
Tuesday, January 16, 2024
Cystic fibrosis, World Health Organization, Patient, Chronic obstructive pulmonary disease, Research, Incidence, Hospital, Inhalation, Agilent Technologies, U22, Ultrasound, Asthma, Administration, Growth, Quality of life, Respiratory system, WHO, Health, Omron, Particle size, Prevalence, Pharmaceutical industry

Among the end users, hospitals and clinics are expected to dominate the global ultrasonic nebulizer market.

Key Points: 
  • Among the end users, hospitals and clinics are expected to dominate the global ultrasonic nebulizer market.
  • Key players operating in the global ultrasonic nebulizer market include Philips Healthcare, Omron, PARI Medical, BD, and Agilent Technologies, among others.
  • Large-volume ultrasonic nebulizers are expected to dominate the global ultrasonic nebulizer market in terms of product type.
  • Overall, the global ultrasonic nebulizer market offers lucrative opportunities in large-volume nebulizers for COPD treatment and the growing demand for home healthcare solutions.

Vida Health Hires Ravi Guha as Chief Financial Officer

Retrieved on: 
Wednesday, January 10, 2024
Cardiology, Software, Biotechnology, Pharmaceutical, General Health, Health, Health Technology, Technology, Diabetes, Obesity, Bass, Chronic obstructive pulmonary disease, Cisco, Bass Pro Shops, Canyon Capital Advisors, Hypertension, Mental health, Risk, Anxiety, Visa, General Motors, Investment, Heart, Depression, Growth, Management

Virtual cardiometabolic care leader Vida Health announced the addition of Ravi Guha to its executive leadership team as Chief Financial Officer.

Key Points: 
  • Virtual cardiometabolic care leader Vida Health announced the addition of Ravi Guha to its executive leadership team as Chief Financial Officer.
  • “I couldn’t be more thrilled to have Ravi as part of our leadership team at Vida,” said Vida Health CEO Joe Murad.
  • While Heal’s Chief Financial Officer, Mr. Guha spearheaded the company’s transition from a fee-for-service urgent care provider to a value-based primary care model.
  • “It’s an honor to be brought on to Vida to lead financial operations at this inflection point of growth for the company,” said Mr. Guha.

Global Airway Management Devices Market Report 2023-2033: Rising Demand for Advanced Airway Management Devices Driven by Surgical Surges and Chronic Illnesses

Retrieved on: 
Tuesday, January 9, 2024
Anesthesia, Growth, Competitive landscape, Airway management, Asthma, Catheter, Chronic obstructive pulmonary disease, Prevalence, COPD, Airline

The escalating demand for airway management devices is primarily propelled by the increasing prevalence of respiratory conditions, particularly Chronic Obstructive Pulmonary Disease (COPD).

Key Points: 
  • The escalating demand for airway management devices is primarily propelled by the increasing prevalence of respiratory conditions, particularly Chronic Obstructive Pulmonary Disease (COPD).
  • Geographically, North America is poised to emerge as a major contributor to the growth of the airway management devices market.
  • What are the major market drivers, challenges and opportunities in the global airway management devices market and their case studies?
  • What is the market share of the leading segments and sub-segments of the global airway management devices market?

Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report

Retrieved on: 
Monday, January 8, 2024
GEJ, Immunoglobulin A, GPRC5D, Government, Trastuzumab, Daiichi Sankyo, DME, BRCA, FDA, Spacecraft, Health, Haemophilia, Abiraterone acetate, Infection, PDE, Crohn's disease, CLVT, Drug discovery, Breast cancer, Breast, Data, Budesonide, AMD, PARP, Metastasis, PDE4, DXD, Safety, NSCLC, Health care, RSV, DR, AstraZeneca, EMA, CRISPR, Chronic obstructive pulmonary disease, Adenocarcinoma, Multiple myeloma, Civil service commission, Artificial intelligence, Patient, Stada Arzneimittel, Intelligence, CD3, Ulcerative colitis, SCD, Lung cancer, European Commission, Sickle cell disease, Gilead Sciences, Respiratory syncytial virus, Research, Diabetic retinopathy, Mirikizumab, COPD, COVID-19, Conditional sentence, Genentech, Thalassemia, Organization, Zolbetuximab, ADC, Pharmaceutical industry

LONDON, Jan. 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the release of its annual Drugs to Watch™ report. The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success. The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.

Key Points: 
  • The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success.
  • The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.
  • Leveraging deep industry expertise and comprehensive therapeutic area differentiated data, this year's Drugs to Watch report identifies innovative medicines based on recent scientific breakthroughs poised to have extraordinary impacts on patient outcomes."
  • Included in Drugs to Watch 2023, a delayed U.S. launch meant that it remains a drug to watch for 2024.

Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report

Retrieved on: 
Monday, January 8, 2024
GEJ, Immunoglobulin A, GPRC5D, Government, Trastuzumab, Daiichi Sankyo, DME, BRCA, FDA, Spacecraft, Health, Haemophilia, Abiraterone acetate, Infection, PDE, Crohn's disease, CLVT, Drug discovery, Breast cancer, Breast, Data, Budesonide, AMD, PARP, Metastasis, PDE4, DXD, Safety, NSCLC, Health care, RSV, DR, AstraZeneca, EMA, CRISPR, Chronic obstructive pulmonary disease, Adenocarcinoma, Multiple myeloma, Civil service commission, Artificial intelligence, Patient, Stada Arzneimittel, Intelligence, CD3, Ulcerative colitis, SCD, Lung cancer, European Commission, Sickle cell disease, Gilead Sciences, Respiratory syncytial virus, Research, Diabetic retinopathy, Mirikizumab, COPD, COVID-19, Conditional sentence, Genentech, Thalassemia, Organization, Zolbetuximab, ADC, Pharmaceutical industry

LONDON, Jan. 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the release of its annual Drugs to Watch™ report. The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success. The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.

Key Points: 
  • The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success.
  • The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.
  • Leveraging deep industry expertise and comprehensive therapeutic area differentiated data, this year's Drugs to Watch report identifies innovative medicines based on recent scientific breakthroughs poised to have extraordinary impacts on patient outcomes."
  • Included in Drugs to Watch 2023, a delayed U.S. launch meant that it remains a drug to watch for 2024.

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, January 4, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Virology, Conference, Heart, Partnership, RSV, FDA, Medication, Chronic obstructive pulmonary disease, Disease, Hepatitis, KIT, Viral load, ADME, Pharmacokinetics, Asthma, COVID-19, CSU, Webcast, Patient, Safety, Therapy, Fast Track, Pharmaceutical industry

Our foundational capabilities in virology and small molecule drug development transition well to immunology, an adjacent field where we can leverage our core strengths.

Key Points: 
  • Our foundational capabilities in virology and small molecule drug development transition well to immunology, an adjacent field where we can leverage our core strengths.
  • The company has developed novel, potent and selective oral inhibitors of KIT, which are now being optimized in preclinical development.
  • Enanta will present new preclinical data on its prototype KIT inhibitor at the J.P. Morgan Conference and is targeting the selection of a development candidate in 2024.
  • A replay of the webcast will be available following the presentation and will be archived for approximately 60 days.

Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 2, 2024
Conference, Atopic dermatitis, COPD, Chronic obstructive pulmonary disease, SAN, Therapy, I&I, Asthma, News

SAN FRANCISCO and WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology (I&I) indications, today announced that Michael Henderson, M.D., Chief Executive Officer of Apogee, will present at the 42nd Annual J.P. Morgan Conference on Tuesday, January 9, 2024 at 7:30 a.m. P.T.

Key Points: 
  • SAN FRANCISCO and WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology (I&I) indications, today announced that Michael Henderson, M.D., Chief Executive Officer of Apogee, will present at the 42nd Annual J.P. Morgan Conference on Tuesday, January 9, 2024 at 7:30 a.m. P.T.
  • / 10:30 a.m. E.T.
  • A live and archived webcast of the presentation will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.